Research Paper Volume 15, Issue 11 pp 4963—4985
FDX1 serves as a prognostic biomarker and promotes glioma progression by regulating the immune response
Figure 8. Silencing FDX1 inhibits PD-L1 expression. (A) GSEA indicates that the NOD-like receptor signaling pathway is positively enriched with high FDX1 expression. (B, C) FDX1 expression is positively associated with NOD1 and PD-L1. (D) FDX1 and PDL1 co-expression confers poorest survival outcomes. (E) NOD1 expression is positively associated with PD-L1. (F) NOD1 and PDL1 co-expression confers the poorest survival outcomes. (G) Western blot indicates that NOD1 and PD-L1 are inhibited after FDX1 silencing. (H) qRT-PCR shows low NOD1 expression after FDX1 silencing.